Autobahn Labs

Name

Autobahn Labs

Legal name

Autobahn Labs LLC

Website

https://autobahn-labs.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Biotech Venture Studio

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)

akta.pro secondary industry

Lab Automation, Instrument Control & Workflow Orchestration Software (HLAGAJAG)

Keywords

• Drug discovery venture studio
• Academic drug development
• Biotech venture creation
• Preclinical therapeutics accelerator
• Academic research translation

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Co-investment in Program Companies: Autobahn receives co-investment from partners like Astellas in startups created under partnership agreements. Selected programs are advanced in newly formed Program Companies with equity shared among Autobahn, the originating academic institution, and academic investigators.
2. Annual Access Fees: Autobahn receives annual access fees from partners such as Astellas for exclusive rights to invest in selected programs from Autobahn's translational research pipeline.
3. Startup Equity Returns: Investment returns realized through equity ownership in jointly-owned companies formed with academic institution partners as they advance toward preclinical development and potential licensing or exit.
4. Project Investment Returns: Up to $5 million invested per project to advance projects to preclinical drug candidates, with returns generated through successful program advancement and licensing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Autobahn Labs operates as a virtual drug discovery venture studio that identifies promising early-stage academic research and forms jointly-owned startup companies with academic institutions. The company provides up to $5 million per project in capital, dedicated operational and scientific expertise, and access to industrialized drug discovery capabilities through its partnership with Charles River Laboratories, advancing programs from therapeutic hypothesis through preclinical drug candidate nomination.

Product overview

Autobahn Labs is a venture studio that operates as a virtual incubator for early-stage drug discovery and development. The company does not offer a single unified product but rather a structured program combining three integrated capital types: Intellectual Capital (operational expertise from industry experts), Physical Capital (access to Charles River Laboratories' drug discovery platform with 3,000+ scientists), and Financial Capital (up to $5M investment per project). Autobahn Labs partners with leading academic institutions to identify promising early science, forms jointly-owned Program Companies, and advances discoveries from therapeutic hypothesis through preclinical drug candidate nomination. The company creates these startups with pre-negotiated institutional agreements enabling rapid exclusive licenses to key university IP.

Differentiator

Problem solved

Functional benefit

Products and services

• Academic Drug Discovery Venture Creation Venture studio program that identifies promising early-stage academic research with therapeutic potential and forms jointly-owned startup companies with academic institutions to advance science from concept to preclinical drug candidate.
• Preclinical Development Services Comprehensive support moving projects from feasibility to preclinical drug candidate nomination, covering medicinal chemistry, genomics, proteomics, CRISPR/shRNA, target validation, hit identification, and preclinical toxicology studies via the Charles River Laboratories integrated platform with access to 3,000+ scientists.

Quantifiable outcome

• Multiple licensing milestones achieved with early university partners (UCLA and UCSF)
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eleven partnerships are on record, tiered core.

• Astellas Pharma Inc.coreStrategic or Co-development Partner · 11 December 2025Strategic partnership granting Astellas exclusive rights to invest in selected programs from Autobahn's translational research pipeline. Autobahn receives an annual access fee and co-investment in startups created. Selected programs advanced in newly formed Program Companies with equity shared among Autobahn, Astellas, academic institutions, and investigators. Astellas retains right of first negotiation for exclusive licensing of jointly funded IP.
• University of MichigancoreStrategic or Co-development Partner · 25 February 2025Strategic collaboration announced through University of Michigan Innovation Partnerships to advance academic discoveries into new medicines.
• University of Southern California (USC)coreStrategic or Co-development Partner · 22 November 2024Strategic collaboration to accelerate drug discovery by advancing promising academic science from USC through Autobahn's venture creation model.
• Charles River LaboratoriescoreStrategic or Co-development Partner · 24 July 2024Preferred research partner providing Autobahn Labs with industry-standard, state-of-the-art drug discovery and development capabilities. Charles River made an equity investment in Autobahn Labs. Justin Bryans, Chief Scientific Officer at Charles River, joined Autobahn's Board of Directors.
• University of PennsylvaniacoreStrategic or Co-development Partner · 2 December 2021Collaboration to identify and support advancement of academic research programs for important unmet medical needs through preclinical candidate selection in drug discovery process.
• Boston Children's HospitalcoreStrategic or Co-development Partner · 2 December 2021Collaboration to identify and advance academic research programs with therapeutic potential through drug discovery and development to positively impact patient health.
• Cold Spring Harbor LaboratorycoreStrategic or Co-development Partner · 7 June 2021Strategic venture collaboration to identify promising research programs with therapeutic potential and partner to form new drug discovery companies. Autobahn invests up to $5M in funding and services into specific programs.
• University of California San Francisco (UCSF)coreStrategic or Co-development Partner · 21 December 2020Strategic collaboration to identify promising early science with therapeutic potential. Organizations partner to establish jointly owned ventures to accelerate translation of scientific ideas to novel therapeutics.
• University of California Los Angeles (UCLA)coreStrategic or Co-development PartnerEarly university partner with exclusive license agreements to foundational technologies. Collaboration focuses on advancing academic research programs targeting unmet medical needs through preclinical candidate selection.
• University of California San Diego (UCSD)coreStrategic or Co-development PartnerUniversity partner collaborating to identify and advance academic research programs for important unmet medical needs through preclinical development.
• Salk Institute for Biological StudiescoreStrategic or Co-development PartnerRecent collaboration to identify academic research programs targeting important unmet medical needs and advance their commercialization in launched companies.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Apollo Therapeutics: UK-based venture studio that partners with top academic institutions (Imperial College London, UCL, Cambridge, King's College London) to translate academic science into drug candidates. Closely analogous to Autobahn in structure and mission.
• BridgeBio Pharma: Genetic-disease focused biotech that in-licenses academic science and creates dedicated subsidiaries around programs, mirroring Autobahn's Program Company model at greater scale and clinical maturity.
• Apple Tree Partners: Biotech venture studio that creates and funds companies around academic and translational science with integrated operational support, directly comparable to Autobahn's venture-creation approach.
• Atlas Venture: Early-stage biotech venture firm that builds companies from academic science with embedded R&D operations, operating a comparable venture-creation model in the biotech space.
• Curie.Bio: Biotech founder-support platform providing capital, operational help, and CRO/research infrastructure to academic spinouts, overlapping with Autobahn's role as a venture-creation partner for academic PIs.
• Medicxi: European asset-centric biotech venture firm that creates and funds companies around single academic-derived programs, comparable to Autobahn's Program Company formation approach.

Broad incumbents

• Charles River Laboratories: CRO and preclinical services giant that is Autobahn's preferred research partner and equity investor; while primarily a service provider, its early-discovery division and venture relationships make it an ecosystem incumbent.
• Evotec SE: Global drug discovery CRO and BRIDGE partnership operator that co-founded Autobahn Labs; broadly comparable as a discovery services and venture-formation platform serving biotech and academic clients.

Others

• Samsara BioCapital: Founding investor of Autobahn Labs and a biotech-focused venture firm; comparable as a thematic biotech investor with academic-sourcing capabilities, though structured as a fund rather than a venture studio.

Emerging players

• Newleos Therapeutics: Early-stage biotech that emerged from academic collaborations; representative of the type of Program Company spinout Autobahn Labs aims to create and fund.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/AutobahnLabs
• LinkedInlinkedin.com/company/autobahn-labs-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Autobahn Labs